Comparing the current results to its competitors, Dexcom Inc reported Revenue increase in the 1 quarter 2026 by 14.99 % year on year. The sales growth was above Dexcom Inc 's competitors' average revenue growth of 9.41 %, achieved in the same quarter.
Dexcom Inc 's Comment on Competition and Industry Peers
The company competes with traditional medical device manufacturers as well as firms outside the traditional medical device sector that develop products and services in the general health, wellness, and population health markets. Some competitors are large, publicly traded companies. These competitors may benefit from FDA guidance that expands the range of products classified as general wellness devices, including wearables that monitor bodily functions and vital signs such as heart rate, blood pressure, and blood glucose. Key competitive factors include product safety, reliability, quality, cost, reimbursement eligibility, comfort, ease of use, sales and marketing effectiveness, brand awareness, customer service, education, speed of innovation, regulatory expertise, and technological leadership.
September 10, 2024
In a pioneering leap for both space exploration and healthcare technology, the Polaris Dawn mission has taken to the stars with an eye not just on the cosmos, but also on human health while navigating the challenges of life beyond Earth. As part of this landmark mission, astronauts are utilizing the Dexcom G6 Continuous Glucose Monitoring (CGM) System, a device that allows real-time monitoring of glucose levels for individuals living with diabetes. This unprecedented application seeks to shed light on the physiological effects of spaceflight on the human body.Launched earlier today from San Diego by DexCom, Inc. (Nasdaq: DXCM), the Polaris Dawn mission aims to explore critical questions surrounding human hea...
August 26, 2024
In a milestone moment for diabetes management, Dexcom, Inc. has launched Stelo, the first over-the-counter glucose biosensor in the United States. This groundbreaking development positions Dexcom as a frontrunner in the healthcare technology sector, addressing the needs of the 125 million Americans living with Type 2 diabetes. Available for purchase without a prescription at Stelo.com, Stelo promises to revolutionize the way individuals monitor their glucose levels which is crucial for effective diabetes management.Stelo is a small, discreet biosensor worn on the back of the upper arm, designed with Dexcom s state-of-the-art glucose sensing technology. This innovative device aims to empower individuals to ta...
August 14, 2024
In a significant development for diabetes care in Quebec, Dexcom, Inc. (NASDAQ: DXCM), a leading innovator in real-time continuous glucose monitoring (rtCGM), has announced that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be included in the public prescription drug insurance plan under the Régie de l assurance maladie du Québec (RAMQ). This expansion comes as a relief for type 1 diabetes patients across the province, providing wider access to state-of-the-art technology that promises to enhance diabetes management.The Dexcom G7, which has been lauded for its compact design, ease of use, and advanced features, is set to transform the daily lives of thousands of Canadians gr...
June 4, 2024
Nova Scotia Expands Coverage for Dexcom Continuous Glucose Monitoring Systems as Dexcom Launches New Sensor and Releases Alarming Type 2 Diabetes ReportResidents of Nova Scotia with type 1 or type 2 diabetes who use intensive insulin therapy now have coverage for Dexcom G6 and Dexcom G7 continuous glucose monitoring (CGM) systems, the global leader in real-time continuous glucose monitoring, Dexcom, Inc., has announced. The coverage is provided through the province s Pharmacare programs and the new income-based Sensor-Based Glucose Monitor initiative.With the rising prevalence of anxiety and depression in individuals with type 2 diabetes, Dexcom has launched the innovative Dexcom ONE+ CGM device, designed to...
May 20, 2024
In a breakthrough development, DexCom, Inc., the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, has unveiled Dexcom ONE+, a cutting-edge CGM device that tracks real-time glucose readings to enhance diabetes management. Simultaneously, Dexcom has released the Dexcom State of Type 2 Report, providing a unique insight into the current landscape of Type 2 diabetes and examining the preferences and behaviors of individuals living with the condition, as well as their caregivers.The Dexcom State of Type 2 Report represents the first of its kind, shedding light on the challenges faced by individuals with Type 2 diabetes. The report aims to raise awareness about the alarming ...
DarioHealth Corp's business model revolves around providing digital health solutions to individuals with chronic diseases. Through their mobile health platform, they offer personalized tools and remote monitoring capabilities that empower patients to proactively manage their conditions. By combining software, data analytics, and medical devices, DarioHealth aims to enhance patient engagement, improve health outcomes, and reduce healthcare costs.
Modular Medical Inc operates with a business model focused on designing and manufacturing modular medical units, offering cost-effective and customizable solutions for healthcare providers looking to expand their facilities rapidly and efficiently. They aim to deliver innovative and turnkey solutions that can be easily deployed and scaled to meet the specific needs of their clients.
Insulet Corporation operates under a business model where they design, develop, and market innovative tubeless insulin delivery systems for people with diabetes. Their main product, the Omnipod System, is a wearable device that provides continuous insulin delivery without the need for traditional insulin pumps and tubing. This unique business model focuses on improving the quality of life for individuals with diabetes by offering a convenient and user-friendly insulin management solution.
Sources:
Dexcom Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dexcom Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
